Semantic Vector Products: Some Initial Investigations. Dominic Widdows. To appear in Second AAAI Symposium on Quantum Interaction, Oxford, 26th – 28th March 2008.
Asymptote is a powerful descriptive vector graphics language that provides a natural coordinate-based framework for technical drawing. Labels and equations are typeset with LaTeX, for high-quality PostScript output.
With DrawBerry, you have all the possibilities the vectorial drawing offers you in a free, easy to use and powerful application. If you don't need applications such Illustrator or Inkscape and you want to create some simple (or less simple) illustrations, DrawBerry is for you.
Revathi. International Journal of Innovative Research in Information Security, 09 (2):
50-54(мая 2023)1. Muhlenbach, F. and Rakotomalala, R. (2015), “Discretization of Continuous Attributes,” In: Wang, J., Ed., Encyclopedia of Data Warehousing and Mining, Idea Group Reference, 397-402. https://doi.org/10.4018/978-1-59140-557-3.ch076 2. M. Liu, D. Zhang, and D. Shen, “Relationship induced multi- 52 template learning for diagnosis of alzheimer’s disease and mild cognitive impairment,” IEEE transactions on medical imaging, vol. 35, no. 6, p. 1463—1474, (2016). https://doi.org/10.1109/tmi.2016.2515021 3. Abdullah Caliskan, Hasan Badem, A. Baştürk, M.E. Yüksel, “Diagnosis Of The Parkinson Disease By Using Deep Neural Network Classifier”, Journal Of Electrical And Electronics Engineering, (2017):3311-3318 4. M. Abdar and M. Zomorodi-Moghadam, “Impact of Patients’ Gender on Parkinson’s disease using Classification Algorithms” Journal of AI and Data Mining, vol. 6, (2018). 5. Sleigh, J.W.; Olofsen, E.; Dahan, A.; de Goede, J.; Steyn-Ross, A. Entropies of the EEG: The effects of general anaesthesia. In Proceedings of the 5th International Conference on Memory, Awareness and Consciousness, New York, NY, USA, 1–3 June (2019) 6. Tsuda, M., Asano, S., Kato, Y., Murai, K., and Miyazaki, M. (2020). Differential diagnosis of multiple system atrophy with predominant parkinsonism and Parkinson's disease using neural networks. J. Neurol. Sci. 401, 19–26. https://doi.org/10.1016/j.jns.2019.04.014 7. Tysnes, O.-B., and Storstein, A. (2021). Epidemiology of Parkinson's disease. J. Neural Trans. 124, 901–905. https://doi:10.1007/s00702-017-1686-y 8. Parkinson J. An Essay on the Shaking Palsy. London: Sherwood, Neely, and Jones; 1817. pp. 1–16. Google Scholar 9. Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson’s disease. Mov Disord. 2003;18:19–31. PubMed Google Scholar 10. National Institute for Health and Care Excellence (NICE) Parkinson’s disease: diagnosis and management in primary and secondary care. NICE clinical guidelines 35. Jun, 2006. Available https://doi.org/10.1136/heartjnl-2022-321095 http://www.nice.org.uk/guidance/cg35/resources/guidance-parkinsons-disease-pdf. Accessed April 28, 2015. 11. Schrag A, Horsfall L, Walters K, et al. Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol. 2015; PubMed Google Scholar https://doi.org/10.1016/s1474-4422(14)70287-x 12. Parkinson’s Disease Foundation Statistics on Parkinson’s. Available at: www.pdf.org.en/parkinson_statistics Accessed June 19, 2014. 13. Driver JA, Logroscino G, Gaziano JM, et al. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology. 2009;72:32–38. PMC free article PubMed Google Scholar https://doi.org/10.1212/01.wnl.0000341769.50075.bb 14. De Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5:525–535. PubMed Google Scholar 15. Miller IN, Cronin-Golomb A. Gender differences in Parkinson’s disease: clinical characteristics and cognition. Mov Disord. 2010;25:2695–2703. PMC free article PubMed Google Scholar https://doi.org/10.1002/mds.23388 16. Rumayor MA, Arrieta O, Sotelo J, et al. Female gender but not cigarette smoking delays the onset of Parkinson’s disease. Clin Neurol Neurosurg. 2009;PubMed Google Scholar https://doi.org/10.1016/j.clineuro.2009.07.012 17. Gómez-Esteban JC, Zarranz JJ, Lezcano E, et al. Influence of motor symptoms upon the quality of life of patients with Parkinson’s disease. Eur Neurol. 2007;57:161–165. PubMed Google Scholar https://doi.org/10.1159/000098468 18. Pennington S, Snell K, Lee M, et al. The cause of death in idiopathic Parkinson’s disease. Parkinsonism Relat Disord. 2010;16:434–437. PubMed Google Scholar https://doi.org/10.1016/j.parkreldis.2010.04.010 19. Jankovic J, Poewe W. Therapies in Parkinson’s disease. Curr Opin Neurol. 2012; PubMed Google Scholar 20. Smith Y, Wichmann T, Factor SA, DeLong MR. Parkinson’s disease therapeutics: new developments and challenges since the introduction of levodopa. Neuropsycho pharmacology. 2012;PMC free article PubMed Google Scholar https://doi.org/10.1038/npp.2011.212 21. Simonson W, Hauser RA, Schapira AHV. Role of the pharmacist in the effective management of wearing-off in Parkinson’s disease. Ann Pharmacother.2007; PubMed Google Scholar https://doi.org/10.1345/aph.1k348 22. Van der Marck MA, Bloem BR, Borm GF, et al. Effectiveness of multidisciplinary care for Parkinson’s disease: a randomized, controlled trial. Mov Disord. 2013;PubMed Google Scholar https://doi.org/10.1002/mds.25194 23. Zhou C, Huang Y, Przedborski S. Oxidative stress in Parkinson’s disease: a mechanism of pathogenic and therapeutic significance. Ann NY Acad Sci. 2008;1147:93–104. PMC free article PubMed Google Scholar https://doi.org/10.1196/annals.1427.023 24. Logroscino G. The role of early-life environmental risk factors in Parkinson disease: what is the evidence? Environ Health Perspect. 2005; PMC free article PubMed Google Scholar https://doi.org/10.1289/ehp.7573 25. Spatola M, Wider C. Genetics of Parkinson’s disease: the yield. Parkinsonism Relat Disord. 2014;20(suppl 1):S35–S38. PubMed Google Scholar https://doi.org/10.1016/s1353-8020(13)70011-7 26. Singleton AB, Farer MJ, Bonifati V. The genetics of Parkinson’s disease: progress and therapeutic implications. Mov Disord. 2013;28:14–23. PMC free article Pu bMed Google Scholar https://doi.org/10.1002/mds.25249 27. Santiago JA, Scherzer CR, Potashkin JA. Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson’s disease. PLoS One. 2014; PMC free article PubMed Google Scholar https://doi.org/10.1371/journal.pone.0109042 28. Liu R, Guo X, Park Y, et al. Caffeine intake, smoking, and risk of Parkinson disease in men and women. Am J Epidemiol. 2012; PMC free article PubMed Google Scholar https://doi.org/10.1093/aje/kwr451 29. Benmoyal-Segal L, Soreq H. Gene–environment interactions in sporadic Parkinson’s disease. J Neurochem. 2006;97:1740–1755. PubMed Google Scholar https://doi.org/10.1111/j.1471-4159.2006.03937.x 30. Van der Merwe C, Haylett W, Harvey J, et al. Factors influencing the development of early- or late-onset Parkinson’s disease in a cohort of South African patients. S Afr Med J. 2012;102:848–851. PubMed Google Scholar https://doi.org/10.7196/samj.5879 31. Wang G, Pan J, Chen SD. Kinases and kinase signaling pathways: potential therapeutic targets in Parkinson’s disease. Prog Neurobiol. 2012; PubMed Google Scholar https://doi.org/10.1016/j.pneurobio.2012.06.003 32. Gilgun-Sherki Y, Djaldetti R, Melamed E, Offen D. Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson’s disease. Pharmacogenomics J. 2004;4:291–306. PubMed Google Scholar https://doi.org/10.1038/sj.tpj.6500260 33. Agúndez JA, García-Martín E, Alonso-Navarro H, et al. Anti-Parkinson’s disease drugs and pharmacogenetic considerations. Expert Opin Drug Metab Toxicol. 2013;9:859–874. PubMed Google Scholar https://doi.org/10.1517/17425255.2013.789018 34. Marras C, Goldman SM. Genetics meets environment: evaluating gene–environment interactions in neurologic diseases. Semin Neurol. 2011;31:553–561. PubMed Google Scholar https://doi.org/10.1055/s-0031-1299793 35. Soreq L, Ben-Shaul Y, Israel Z, et al. Meta-analysis of genetic and environmental Parkinson’s disease models reveals a common role of mitochondrial protection pathways. Neurobiol Dis. 2012;45:1018–1030. PubMed Google Scholar https://doi.org/10.1016/j.nbd.2011.12.021 36. Curtin K, Fleckenstein AE, Robison RJ, et al. Methamphetamine/amphetamine abuse and risk of Parkinson’s disease in Utah: a population-based assessment. Drug Alcohol Depend. 2015;146:30–38. PMC free article PubMed Google Scholar https://doi.org/10.1016/j.drugalcdep.2014.10.027 37. Chen JJ, Swope DM. Parkinson’s disease. In: DiPiro JT, Talbert RL, Yee GC, et al., editors. Pharmacotherapy: A Pathophysiologic Approach. 9th ed. New York, New York: McGraw-Hill; 2014. Google Scholar 38. Chade AR, Kasten M, Tanner CM. Nongenetic causes of Parkinson’s disease. J Neural Transm Suppl. 2006;70:147–151. PubMed Google Scholar https://doi.org/10.1007/978-3-211-45295-0_23.
L. Li, H. Wang, T. Chin, D. Suter, и S. Zhang. Image and Signal Processing (CISP), 2010 3rd International Congress on, 4, стр. 1586 -1589. (октября 2010)